Boehringer Ingelheim Vetmedica Inc. (BIVI), has received FDA approval to market Prascend (pergolide mesylate) for treatment of clinical signs associated with pituitary pars intermedia dysfunction (PPID), also known as equine Cushing's disease.
To continue reading this article, become a member of TheHorse.com.
It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.










